3rd Quarter - Report

BIOCOM for BIOCOM

Firm
Client
Income
—
Expenses
$45,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Advocated against drug pricing legislation HR3, as a stand-alone bill and as a provision in the FY2022 reconciliation package. Submitted comments on the Cures 2.0 draft legislation Advocated for antimicrobial resistance legislation

LobbyistCovered position, as disclosed
LAURE FABREGA CLARK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3 (117th)

Taxation/Internal Revenue Code TAX

Expressed concerns with tax provisions in the FY2022 reconciliation bill, including raising the corporate tax rate and limiting the orphan drug tax credit

LobbyistCovered position, as disclosed
LAURE FABREGA CLARK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Expressed importance of intellectual property protections for the life science industry. Expressed opposition to the Administration's decision to support waiving IP protections for covid-19 vaccines under the TRIPS agreement.

LobbyistCovered position, as disclosed
LAURE FABREGA CLARK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.